After two flops, Roche and Exelixis post early PhIII win for Tecentriq/Cabometyx combo — but will wait for OS data

Amber Tong

Roche and Exelixis have finally notched a Phase III win with the combination of Tecentriq and Cabometyx, clearing the progression-free survival bar in metastatic castration …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

After two flops, Roche and Exelixis post early PhIII win for Tecentriq/Cabometyx combo — but will wait for OS data

Amber Tong

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

Omada Health is going public on Friday at a $1.1B valuation

FDA's Makary looks at ways to speed drug approvals, talks about cutting user fees

Trump's health appointees pledge support for cell and gene therapies at FDA roundtable

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Af­ter two flops, Roche and Ex­elix­is post ear­ly PhI­II win for Tecen­triq/Cabome­tyx com­bo — but will wait for OS da­ta

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

After two flops, Roche and Exelixis post early PhIII win for Tecentriq/Cabometyx combo — but will wait for OS data